This compound serves as a protected intermediate in the pharmaceutical industry for the synthesis of decitabine (5-aza-2'-deoxycytidine), a nucleoside analog used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Its structure mimics cytidine, allowing incorporation into DNA where it inhibits DNA methyltransferases, leading to hypomethylation and antitumor effects. The 3',5'-di-O-(4-chlorobenzoyl) protecting groups facilitate selective synthesis and purification during production. The specific stereochemistry (2R,3S,5R) ensures the beta-D-2'-deoxyribofuranosyl configuration essential for biological activity. Researchers also investigate its role in epigenetic therapies for other cancers and potential non-oncological applications leveraging DNA demethylation.